Volume 88, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



Our study investigated the possible impact of SP-IPT given to infants and children on the prevalence of SP-resistant haplotypes in the genes and , comparing sites with and without IPTi/c. positive samples (N = 352) collected from children < 5 years were analyzed to determine the prevalence of SP resistance-related haplotypes by nested PCR followed by sequence-specific oligonucleotide probe-enzyme-linked immunosorbent assay. The prevalence of the triple mutant haplotype (CIRN) increased in both groups, but only significantly in the IPTi/c group from 41% to 65% in 2011 ( = 0.005). Conversely, the 437G mutation decreased in both groups from 44.6% to 28.6% ( = 0.07) and from 66.7% to 47.5% ( = 0.02) between 2010 and 2011 in the control and the IPTi/c groups, respectively. A weak trend for decreasing prevalence of quadruple mutants (triple + 437G) was noted in both groups ( = 0.15 and = 0.34). During the two cross-sectional surveys some significant changes were observed in the SP resistance-related genes.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Le Bras J, Musset L, Clain J, , 2006. Antimalarial drug resistance. Med Mal Infect 36: 401405.[Crossref] [Google Scholar]
  2. Greenwood B, , 2004. The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am J Trop Med Hyg 70: 17. [Google Scholar]
  3. National Malaria Control Program, 2003. National Consensus Workshop on Malaria Treatment Policy in Senegal. Dakar, Senegal: Ministry of Health, Hygiene and Prevention. 71 pp. [Google Scholar]
  4. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C, , 2009. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374: 15331542.[Crossref] [Google Scholar]
  5. Grobusch MP, Egan A, Gosling RD, Newman RD, , 2007. Intermittent preventive therapy for malaria: progress and future directions. Infect Dis 20: 613620. [Google Scholar]
  6. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D, , 2009. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double- blind, placebo-controlled trial. Lancet 374: 15211532.[Crossref] [Google Scholar]
  7. Etard JF, Le Hesran JY, Diallo A, Diallo JP, Ndiaye JL, Delaunay V, , 2004. Childhood mortality and probable causes of death using verbal autopsy in Niakhar, Senegal, 1998–2000. Int J Epidemiol 33: 12861292.[Crossref] [Google Scholar]
  8. Jaffar S, Leach A, Greenwood AM, Jepson A, Muller O, Ota MO, Bojang K, Obaro S, Greenwood BM, , 1997. Changes in the pattern of infant and childhood mortality in upper river division, The Gambia, from 1989 to 1993. Trop Med Int Health 2: 2837.[Crossref] [Google Scholar]
  9. Wilson AL, IPTc Taskforce, , 2011. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS ONE 6: e16976.[Crossref] [Google Scholar]
  10. Cisse B, Faye S, Dial Y, Faye O, Gaye O, , 2007. Pilot study of the implementation of seasonal intermittent treatment in children (IPTc) with community participation in Senegal. Trop Med Int Health (Suppl 1): 46.02540. [Google Scholar]
  11. Chandramohan D, Owusu-Agyei S, Carneiro I, Awine T, Amponsa-Achiano K, Mensah N, Jaffar S, Baiden R, Hodgson A, Binka F, Greenwood B, , 2005. Cluster randomized trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331: 727733.[Crossref] [Google Scholar]
  12. Cissé B, Sokhna C, Boulanger D, Milet J, EH, Richardson K, Hallett R, Sutherland C, Simondon K, Simondon F, Neal A, Gaye O, Targett G, Lines J, Greenwood B, Trape JF, , 2006. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-blind trial. Lancet 367: 659667.[Crossref] [Google Scholar]
  13. WHO, 2012. Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum Malaria Control in Highly Seasonal Transmission Areas of the Sahel Sub-Region in Africa. Available at: http://www.who.int/malaria/mpac/feb2012/mpac_article_03_2012.pdf. Accessed October 15, 2012. [Google Scholar]
  14. Cowman AF, Morry MJ, Biggs BA, Cross GA, Foote SJ, , 1988. Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum . Proc Natl Acad Sci USA 85: 91099113.[Crossref] [Google Scholar]
  15. Peterson DS, Walliker D, Wellems TE, , 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci USA 85: 91149118.[Crossref] [Google Scholar]
  16. Brooks DR, Wang P, Read M, Watkins WM, Sims PF, Hyde JE, , 1994. Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur J Biochem 224: 397405.[Crossref] [Google Scholar]
  17. Triglia T, Cowman AF, , 1994. Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum . Proc Natl Acad Sci USA 91: 71497153.[Crossref] [Google Scholar]
  18. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, Khalil IF, Theander TG, Lemnge MM, Bygbjerg IC, , 2009. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Am J Trop Med Hyg 80: 523527. [Google Scholar]
  19. Staedke SG, Sendagire H, Lamola S, Kamya MR, Dorsey G, Rosenthal PJ, , 2004. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health 9: 624629.[Crossref] [Google Scholar]
  20. Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM, , 2005. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop 95: 183193.[Crossref] [Google Scholar]
  21. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, , 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis 185: 380388.[Crossref] [Google Scholar]
  22. Nzila AM, Nduati E, Mberu EK, Sibley CH, Monks SA, Winstanley PA, Watkins WM, , 2000. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum . JID 181: 20232028.[Crossref] [Google Scholar]
  23. Omar SA, Adagu IS, Warhurst DC, , 2001. Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans R Soc Trop Med Hyg 95: 315319.[Crossref] [Google Scholar]
  24. WHO, 2009. Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), Technical Expert Group on Preventive Chemotherapy. WHO TEG IPTi Report April 2009. Geneva: World Health Organization, 111. [Google Scholar]
  25. Dia I, Diop T, Rakotoarivony I, Kengne P, Fontenille D, , 2003. Bionomics of Anopheles gambiae Giles, An. arabiensis Patton, An. funestus Giles and An. nili (Theobald) (Diptera: Culicidae) and transmission of Plasmodium falciparum in a Sudano-Guinean zone (Ngari, Senegal). J Med Entomol 40: 279283.[Crossref] [Google Scholar]
  26. Wooden J, Kyes S, Sibley CH, , 1993. PCR and strain identification in Plasmodium falciparum . Parasitol Today 9: 303305.[Crossref] [Google Scholar]
  27. Pearce RJ, Drakeley C, Chandramohan D, Mosha F, Roper C, , 2003. Molecular determination of point mutation haplotypes in the dihydrofolate reductase and dihydropteroate synthase of Plasmodium falciparum in three districts of northern Tanzania. Antimicrob Agents Chemother 47: 13471354.[Crossref] [Google Scholar]
  28. Alifrangis M, Enosse S, Pearce R, Drakeley C, Roper C, Khalil IF, Nkya WM, Ronn AM, Theander TG, Bygjerg IB, , 2005. A simple, high-throughput method to detect Plasmodium falciparum single nucleotide polymorphisms in the dihydrofolate reductase, dihydropteroate synthase, and P. falciparum chloroquine resistance transporter genes using polymerase chain reaction- and enzyme-linked immunosorbent assay-based technology. AJTMH 72: 155162. [Google Scholar]
  29. Faye B, Ndiaye M, Ndiaye JL, Annie A, Tine RC, Lo AC, Ndiaye M, Sow D, De Sousa A, Gaye O, , 2011. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine–pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol Res 109: 133138.[Crossref] [Google Scholar]
  30. Menéndez C, D'Alessandro U, ter Kuile FO, , 2007. Reducing the burden of malaria in pregnancy by preventive strategies. Lancet Infect Dis 7: 126135.[Crossref] [Google Scholar]
  31. Crawley J, Hill J, Yartey J, Robalo M, Serufilira A, Ba-Nguz A, Roman E, Palmer A, Asamoa K, Steketee R, , 2007. From evidence to action? Challenges to policy change and programme delivery for malaria in pregnancy. Lancet Infect Dis 7: 145155.[Crossref] [Google Scholar]
  32. Mbaye A, Richardson K, Balajo B, Dunyo S, Shulman C, Milligan P, Greenwood B, Walraven G, , 2006. A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. Trop Med Int Health 11: 9921002.[Crossref] [Google Scholar]
  33. Dicko A, Sagara I, Djimdé AA, Touré SO, Traore M, Dama S, Diallo AI, Barry A, Dicko M, Coulibaly OM, Rogier C, de Sousa A, Doumbo OK, , 2010. Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali. Malar J 9: 9.[Crossref] [Google Scholar]
  34. Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E, Mandomando I, Puyol L, Berzosa P, Dobaño C, Aide P, Sacarlal J, Benito A, Alonso P, Menéndez C, , 2008. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis 197: 17371742.[Crossref] [Google Scholar]

Data & Media loading...

  • Received : 10 Dec 2012
  • Accepted : 21 Jan 2013
  • Published online : 05 Jun 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error